大规格缓释片潜在药物性胃石形成及其溶出度的体外研究
该研究建立模拟胃液的体外模型,将30片缓释片(喹硫平/XR 50mg、对乙酰氨基酚/Pinex Retard 500mg、维拉帕米/Isoptin Retard 240mg、卡马西平/Tegretol Retard 200mg)及即释对乙酰氨基酚/Panodil 500mg分别置于聚酰胺网袋中,在1L模拟胃液37°C孵育48小时。结果显示喹硫平/XR、Pinex Retard和Isoptin Retard形成坚硬药物性胃石,稳定超过4小时,完整碎片持续达24小时,药物释放较分离片剂分别降低53%、40%和31%(至8小时)。Tegretol Retard 30分钟内崩解为微球,Panodil数分钟内崩解。形成的药物性胃石和单个缓释片均无法通过标准30F胃管,提示胃灌洗对这类制剂清除无效。
要点
- 喹硫平/XR、对乙酰氨基酚/Pinex Retard和维拉帕米/Isoptin Retard大量摄入后形成药物性胃石,稳定超过4小时,完整碎片达24小时。
- 与分离片剂相比,上述三种缓释片形成胃石后药物释放分别降低53%、40%和31%(至8小时),可能延长中毒时程。
- Tegretol Retard 30分钟内崩解为微球,Panodil数分钟内崩解,未见胃石形成。
- 形成的药物性胃石及单个缓释片均无法通过30F胃管,提示胃灌洗对该类制剂清除无效。
- 作者认为,口服活性炭通常足以阻止药物吸收,但在近期大量摄入高毒物质时,可考虑先前进行胃灌洗。
适用人群与场景
- 模拟大量摄入缓释片 overdose 的体外模型,非患者人群。
研究设计与关键结果
- 研究类型为体外实验,使用标准化模型模拟胃液对制剂的影响,测试三种单储库缓释片(喹硫平/Seroquel XR 50mg、对乙酰氨基酚/Pinex Retard 500mg、维拉帕米/Isoptin Retard 240mg)、一种多储库缓释片(卡马西平/Tegretol Retard 200mg)和一种即释片(对乙酰氨基酚/Panodil 500mg)。
- 将30片药片置于聚酰胺网袋中(合在一起或分开),浸入1L模拟胃液,37°C孵育48小时,在0.5-48小时量化药物释放。
- 视觉检查显示Seroquel XR、Pinex Retard和Isoptin Retard形成坚硬药物性胃石,稳定超过4小时,完整碎片持续达24小时。
- 与分离片剂相比,Seroquel XR、Pinex Retard和Isoptin Retard的药物释放分别降低53%、40%和31%(至8小时)。
- 光学显微镜显示Seroquel XR和Pinex Retard的包衣接触模拟胃液后转变为扩散控制的溶胀凝胶层,Isoptin Retard转变为坚硬且缓慢释放的基质。
- Tegretol Retard在30分钟内崩解为微球,Panodil在数分钟内崩解。
证据类型、等级与局限
- 证据类型:体外研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,口服活性炭通常足以阻止药物吸收,但在近期大量摄入高毒物质时,可考虑先前进行胃灌洗。
- 作者认为,形成的药物性胃石和单个缓释片均无法通过标准30F胃管,使胃灌洗在胃肠道去污中对片剂清除无效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Extended release (ER) tablets/capsules in massive ingestion overdoses are prone to form pharmacobezoars potentially increasing the risk of late-appearing toxic effects and prolonged symptoms. Oral activated charcoal is often sufficient to prevent drug absorption, but in a recent massive ingestion of highly toxic substances, prior orogastric lavage might be considered. The disintegration characteristics of ER preparations in overdose situations is valuable to understand if the time line and course of the intoxication might be prolonged, but information on these characteristics are unavailable. Slow disintegration and/or pharmacobezoar formation, and the large size makes ER preparation impossible to evacuate using a 30F orogastric lavage tube. This study evaluates the disintegration and pharmacobezoar formation of a simulated massive ER tablet ingestion in an in vitro model, using a selection of extended release tablets, with different disintegrating characteristics when present in therapeutic numbers. Furthermore, the sizes of the formed pharmacobezoars were compared with the dimensions of a 30F orogastric lavage tube.
METHOD: A standardized model mimicking the physical effects on pharmaceutical preparations in simulated gastric fluid (SGF) was developed and tested on three mono-depot ER tablets (quetiapine/Seroquel®XR 50 mg, paracetamol/Pinex®Retard 500 mg, verapamil/Isoptin®Retard 240 mg), one poly-depot ER tablet (carbamazepine/Tegretol®Retard 200 mg), and one immediate-release tablet (paracetamol/Panodil® 500mg). Thirty tablets were placed in polyamide mesh bags, either together in one bag or in separate bags, immersed in 1 L SGF, and incubated at 37 °C for 48 h. Released drugs were quantified at 0.5-48 h.
RESULTS: Visual inspection showed that Seroquel®XR, Pinex®Retard, and Isoptin®Retard tablets formed firm pharmacobezoars stable for more than 4 h and intact fractions remained for up to 24 h. Drug releases were reduced by 53%, 40%, and 31%, respectively, for up to 8 h compared to separated tablets. Light microscopy showed that contact with SGF transformed the coating of Seroquel®XR and Pinex®Retard to a diffusion-controlled swelled gel-layer, and the Isoptin®Retard tablets into a rigid and slow-releasing matrix. Tegretol®Retard disintegrated into microspheres within 30 min, and Panodil® disintegrated within minutes.
DISCUSSION: The developed pharmacobezoars of mono-depot ER tablets demonstrated prolonged drug release. Neither the formed pharmacobezoars, nor the single tablets of the tested mono-depot ER preparations, would pass through the lumen of a standard orogastric lavage tube, rendering this modality ineffective for tablet removal in gastrointestinal decontamination.
参考来源
- Hoegberg LCG, Refsgaard F, Pedersen SH, et al. Potential pharmacobezoar formation of large size extended-release tablets and their dissolution - an in vitro study. Clin Toxicol (Phila). 2018. PMID: 30306811. doi:10.1080/15563650.2018.1513138
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。